MA31699B1 - Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3 - Google Patents

Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3

Info

Publication number
MA31699B1
MA31699B1 MA32688A MA32688A MA31699B1 MA 31699 B1 MA31699 B1 MA 31699B1 MA 32688 A MA32688 A MA 32688A MA 32688 A MA32688 A MA 32688A MA 31699 B1 MA31699 B1 MA 31699B1
Authority
MA
Morocco
Prior art keywords
histamine
isokinolinil
isoendolinil
receptors
derivatives
Prior art date
Application number
MA32688A
Other languages
Arabic (ar)
English (en)
Inventor
Dahui Zhou
Jonathan Laird Gross
Albert Jean Robichaud
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MA31699B1 publication Critical patent/MA31699B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un composé représenté par la formule (i) et son utilisation pour le traitement d'un trouble du système nerveux central en relation avec ou affecté par le récepteur de l'histamine-3.
MA32688A 2007-09-12 2010-03-12 Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3 MA31699B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99363607P 2007-09-12 2007-09-12
PCT/US2008/075981 WO2009036144A1 (fr) 2007-09-12 2008-09-11 Dérivés d'isoquinolinyle et d'isoindolinyle convenant comme antagonistes de l'histamine-3

Publications (1)

Publication Number Publication Date
MA31699B1 true MA31699B1 (fr) 2010-09-01

Family

ID=40261509

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32688A MA31699B1 (fr) 2007-09-12 2010-03-12 Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3

Country Status (25)

Country Link
US (1) US20090069300A1 (fr)
EP (1) EP2200989A1 (fr)
JP (1) JP2010539180A (fr)
KR (1) KR20100054856A (fr)
CN (1) CN101848896A (fr)
AP (1) AP2010005202A0 (fr)
AR (1) AR068423A1 (fr)
AU (1) AU2008298926A1 (fr)
BR (1) BRPI0817061A2 (fr)
CA (1) CA2699384A1 (fr)
CL (1) CL2008002726A1 (fr)
CO (1) CO6300955A2 (fr)
CR (1) CR11303A (fr)
DO (1) DOP2010000079A (fr)
EA (1) EA201000316A1 (fr)
EC (1) ECSP10010025A (fr)
MA (1) MA31699B1 (fr)
MX (1) MX2010002760A (fr)
NI (1) NI201000036A (fr)
PA (1) PA8795701A1 (fr)
PE (1) PE20090651A1 (fr)
TN (1) TN2010000105A1 (fr)
TW (1) TW200927114A (fr)
WO (1) WO2009036144A1 (fr)
ZA (1) ZA201001751B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
GB0907284D0 (en) 2009-04-28 2009-06-10 Queen Mary & Westfield College Compounds for inducing cellular apoptosis
PT2464645T (pt) * 2009-07-27 2017-10-11 Gilead Sciences Inc Compostos heterocíclicos fusionados como moduladores do canal de iões
WO2012003392A1 (fr) 2010-07-02 2012-01-05 Gilead Sciences, Inc. Composés hétérocycliques condensés en tant que modulateurs des canaux ioniques
EP2632461A4 (fr) * 2010-10-29 2014-04-02 Merck Sharp & Dohme Composés d'isoindolinone utiles comme inhibiteurs de pde 10
AU2012253653A1 (en) * 2011-05-10 2013-05-02 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (fr) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
US9173395B2 (en) 2011-07-04 2015-11-03 Bayer Intellectual Property Gmbh Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants
WO2013076590A1 (fr) 2011-11-23 2013-05-30 Oxygen Healthcare Research Pvt. Ltd Composés benzothiazines en tant que ligands de récepteur h3
CN105254554B (zh) * 2014-07-14 2018-01-30 南开大学 一种制备异吲哚啉酮类化合物的方法
US20230167093A1 (en) * 2020-04-08 2023-06-01 Remix Therapeutics Inc. Compounds and methods for modulating splicing
EP4203952A4 (fr) 2020-08-28 2024-12-11 Kumquat Biosciences Inc. Composés hétérocycliques et leurs utilisations
US12496297B1 (en) * 2020-10-23 2025-12-16 Washington University Compositions of autophagy modulating agents and uses thereof
CN115819347B (zh) * 2022-11-14 2024-08-30 暨明医药科技（苏州）有限公司 一种1-烷基-3-溴吡唑的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
CA2287984A1 (fr) * 1997-05-01 1998-11-05 Gerald Floyd Smith Agents antithrombotiques
WO2002076925A2 (fr) 2001-03-23 2002-10-03 Eli Lilly And Company Composes d'aryl alkylamines non imidazole comme antagonistes des recepteurs h3 de l'histamine, preparation et applications therapeutiques
MY140236A (en) * 2002-09-19 2009-12-31 Lilly Co Eli Diarylether compounds useful as opioid receptor antagonists
ATE381566T1 (de) * 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
EP1848696A1 (fr) * 2005-01-21 2007-10-31 Schering Corporation Derives d'imidazole et de benzimidazole utiles en tant qu'antagonistes de l'histamine h3
JP2008537953A (ja) * 2005-04-15 2008-10-02 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンｂ１受容体拮抗作用に有用な新規化合物

Also Published As

Publication number Publication date
AR068423A1 (es) 2009-11-18
CL2008002726A1 (es) 2008-10-10
WO2009036144A1 (fr) 2009-03-19
EP2200989A1 (fr) 2010-06-30
ZA201001751B (en) 2010-11-24
PA8795701A1 (es) 2009-04-23
DOP2010000079A (es) 2010-03-31
BRPI0817061A2 (pt) 2015-03-24
NI201000036A (es) 2010-08-13
ECSP10010025A (es) 2010-08-31
MX2010002760A (es) 2010-04-01
EA201000316A1 (ru) 2010-10-29
JP2010539180A (ja) 2010-12-16
CR11303A (es) 2010-03-18
CA2699384A1 (fr) 2009-03-19
TN2010000105A1 (fr) 2011-09-26
AP2010005202A0 (en) 2010-04-30
PE20090651A1 (es) 2009-05-28
AU2008298926A1 (en) 2009-03-19
US20090069300A1 (en) 2009-03-12
TW200927114A (en) 2009-07-01
CO6300955A2 (es) 2011-07-21
CN101848896A (zh) 2010-09-29
KR20100054856A (ko) 2010-05-25

Similar Documents

Publication Publication Date Title
MA31700B1 (fr) Derives d'azacyclylisoquinolinone et -isoindolinone servant d'antagonistes du recepteur d'histamine-3
TN2010000105A1 (fr) Derives d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du recepteur d'histamine -3
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
MA30991B1 (fr) Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
WO2007136668A3 (fr) N-benzoyle et n-benzylpyrrolidin-3-ylamines comme antagonistes de l'histamine-3
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA31593B1 (fr) Derives de 2-aza-bicyclo[3.3.0]octane
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA31910B1 (fr) Antagonistes des recepteurs non steroidiens des mineralocorticoides derives de la 6h-dibenzo[b,e]oxepine
EA200970326A1 (ru) Алкильные производные в качестве метаботропных рецепторов глутамата
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
CO6190517A2 (es) Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f]indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide
MY155212A (en) Quaternary ammonium salt compounds
WO2008056259A3 (fr) Dérivés d'oxazole utilisés en tant que modulateurs allostériques positifs des récepteurs métabotropiques du glutamate
MA33559B1 (fr) Composes bicycliques 5,6- heteroaryle contenant l'uree comme inhibiteurs de kinase.
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique